Obese, Obesity
Conditions
Keywords
comorbidities, PronoKal® Method, Cost-Benefit Analysis, loss weight, obesity
Brief summary
Prospective, observational, multicenter study based on a registry of patients with obesity and associated comorbidities undergoing a standardized multidisciplinary weight loss method with a 2-year follow-up.
Detailed description
The investigators will include obese patients with BMI higher than 30 kg / m2 and one or more comorbidities associated with obesity who are following a standardized multidisciplinary weight-loss program (PronoKal® Method), which consists of a very-low-calorie diet, into which natural foods are gradually reintroduced, accompanied by physical exercise and emotional support. The aim of this study is to assess the cost-effectiveness to improve the health condition of obese patients with comorbidities and thereby reduce healthcare expenditure (pharmacological treatment, incidence of complications, use of health resources) and work absenteeism. Patients will be monitored for 2 years. The registry of patient data for this study will be made by the doctor and dietitians / nutritionists who will regularly see the patient in the face-to-face visits at the Pronokal center. The study will begin with the baseline visit (day 0) in which the inclusion and exclusion criteria will be confirmed, the signing of informed consent will be obtained and the multidisciplinary treatment will be prescribed, followed by 6 control visits: 2 visits during the ketogenic stage (1-month after the start and at the end of ketosis), 2 visits during the physiological adaptation phase (at 4 or 5 months and at the end of stage 2) and 2 follow-up visits during the maintenance up to the 2-year completion. Likewise, dietitians/nutritionists, according to the methodology of the program, will carry out a face-to-face follow-up of the patient, which will be fortnightly during the ketogenic diet, monthly during the physiological adaptation of stage 2 and quarterly or semi-annual during the maintenance stage. The information about the endpoints will be collected: * Costs of weight loss treatment: products and dietary supplements + number of control visits + number of laboratory tests performed * Healthcare expenditure: pharmacological treatment of associated comorbidities, incidence of complications (visits to his/her primary care physician, a specialist or emergency department for acute complications, treatment of acute complications, number of hospital admission days, antibiotic treatment), consumption of health resources (visits to the general practitioner, visits to specialists, laboratory tests) * Work absenteeism: number of work leave days + hours of work absenteeism due to health problems or medical visits.
Interventions
None listed
Sponsors
Protein Supplies SL
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients of both sexes 18 years of age or older * Patients with overweight or obesity (BMI\> 30 kg/m2) with at least one or more of the following comorbidities associated with obesity (type 2 diabetes mellitus, arterial hypertension, dyslipidemia, hyperuricemia) those who are under pharmacological treatment with two or more drugs (oral antidiabetic and/or lipid-lowering agents and/or antihypertensive and/or hypouricemic agents) * Patients who agree to attend the follow-up visits at the Pronokal centre, in Buenos Aires. * Patients who agree to participate and provide a signed informed consent
Exclusion criteria
* Patients who do not sign the informed consent * Pregnant or breastfeeding patients. * Patients with severe eating disorders, alcoholism, or substance abuse. * Patients with severe psychological disorders (e.g., schizophrenia, bipolar disorder). * Patients with liver failure. * Patients with kidney failure. * Patients with type 1 DM or insulin-dependent, or currently under insulin treatment, or candidates for insulin treatment in a short period of time. * Patients with obesity caused by other endocrine diseases (except type 2 DM). * Patients with blood disorders. * Patients with cancer. * Patients with cardiovascular or cerebrovascular disease (heart rhythm disorders, recent infarction \[\<6m\], unstable angina, decompensated heart failure, recent stroke \[\<6m\]). * Patients with renal lithiasis. * Patients with cholelithiasis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Healthcare expenditure for one year | 1 year | Sum of the following costs: pharmacological treatment of associated comorbidities + visits to primary care physician + visits to specialist + visits to emergency department for acute complications +treatment for acute complications +number of hospital admission days + antibiotic treatment +laboratory tests, for one year (from baseline to 1 year) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Healthcare expenditure the second year | 2 years | Sum of the following costs: pharmacological treatment of associated comorbidities + visits to primary care physician + visits to specialist + visits to emergency department for acute complications +treatment for acute complications +number of hospital admission days + antibiotic treatment +laboratory tests, from 1 to 2 years |
| Monthly costs of pharmacological treatment of obesity comorbidities (after 2 years) | 2 years | Sum of the pharmacological treatment of associated comorbidities (Antidiabetics + Antihypertensives + Statins / lipid-lowering + treatment of hyperuricemia+ Other treatments of obesity comorbidities after 2 years |
| Work absenteeism for 1 year | 1 year | Number of absences from work (days and hours) due to health problems or medical visits, from baseline from baseline to 1 year |
| Work absenteeism the second year | 2 years | Number of absences from work (days and hours) due to health problems or medical visits, from baseline from 1 to 2 years |
| Body weight loss | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change of body weight from baseline to end of treatment |
| Waist circumference reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change of Waist circumference from baseline to end of treatment |
| Blood glucose reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in levels of blood glucose from baseline to the end of treatment |
| Glycosylated hemoglobin reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in percentage of glycosylated hemoglobin from baseline to the end of treatment |
| Monthly costs of pharmacological treatment of obesity comorbidities (after one year) | 1 year | Sum of the pharmacological treatment of associated comorbidities (Antidiabetics + Antihypertensives + Statins / lipid-lowering + treatment of hyperuricemia+ Other treatments of obesity comorbidities |
| LDL-cholesterol reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in levels of LDL-cholesterol from baseline to the end of treatment |
| HDL-cholesterol increase | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in levels of HDL-cholesterol from baseline at the end of treatment |
| Triglycerides reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in levels of triglycerides from baseline at the end of treatment |
| Serum uric acid reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in levels of serum uric acid from baseline at the end of treatment |
| Systolic blood pressure reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in systolic blood pressure from baseline at the end of treatment |
| Diastolic blood pressure reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in diastolic blood pressure from baseline at the end of treatment |
| Quality of life (score) | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in score in the Short-Form General Health Survey (SF-12) questionnaire from baseline to end of treatment. Raw scores will be calculated as the sum of (re-coded) scale items and transformed to a 0 (negative response) to 100 (positive response) scale. A higher score indicates a better QoL; a positive change (increase in score) in score indicates improvements in QoL while negative change (decrease in score) indicates deterioration. |
| Number of Participants With Adverse Events | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Number of Participants With Adverse Events as a Measure of Safety and Tolerability |
| Total cholesterol reduction | from baseline through treatment completion, an average of 6 months in patients with an initial body mass index of 30 to 35 kg/m2 and an average of 9 months for those patients with initial body mass index higher than 35 kg/m2. | Change in levels of total cholesterol from baseline to the end of treatment |
Countries
Argentina
Outcome results
None listed